1. In this randomized controlled trial, rates of ventilator-associated pneumonia (VAP) were lower in ventilated patients using amikacin as compared to a placebo. 2. This difference was maintained over a 28-day follow-up period in the amikacin group. Evidence Rating Level: 1 (Excellent) Study Rundown: VAP emerges 48 hours or more post-mechanical ventilation via an endotracheal
1. In this randomized controlled trial, ventilator-associated pneumonia (VAP) was prevented by employing inhaled amikacin in mechanically ventilated patients exceeding three-day duration. 2. Inhaled amikacin was associated with a reduction in VAP incidence during a 28-day follow-up period. Evidence Rating Level: 1 (Excellent) Study Rundown: VAP typically occurs 48 hours or more post-mechanical ventilation via
Inhaled amikacin reduces ventilatory-associated pneumonia medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.